摘要
目的:探讨首发精神分裂症患者COMT基因多态性与利培酮疗效的关系。方法:100例首发精神分裂症患者使用利培酮治疗8周,以PANSS量表评定疗效;SNaPshot SNP检测COMT基因rs4680和rs4818多态性。结果:利培酮有效组与无效组相比,精神分裂症患者rs4680基因型G/G与A/G、A/A的分布差异具有显著性(χ2=5.334,P<0.05),rs4680G/G基因型与利培酮疗效之间存在明显关联(OR=1.78,P<0.05)。结论:rs4680多态性与利培酮治疗首发精神分裂症的临床疗效相关。
Objective To investigate the association of catechol-O-methyltransferase （COMT） gene polymorphisms with response of risperidone treatment in first-episode schizophrenia. Methods One hundred cases of schizophrenic patients were chosen to treat with risperidone for 8 weeks. The efficacy of antipsychotic medication was evaluated by PANSS scale. Allelic typing of COMT was detected by SNaPshot SNP technique. Results The distribution of rs4680 genotype G/G, A/G and A/A had significant difference between risperidone responder group and nonresponder group （χ2 = 5.334,P 〈 0.05） and rs4680 G/G genotype was correlated with the efficacy of risperidone （OR = 1.78, P 〈 0.05 ）. Conclusion The polymorphisms of rs4680 related with effects of risperidone on first-episode schizophrenia.
出处
《实用医学杂志》
CAS
北大核心
2013年第4期625-627,共3页
The Journal of Practical Medicine
基金
广东省科技计划项目(编号:2009B030801372)
